Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Polyphor AG
  6. News
  7. Summary
    POLN   CH0106213793

POLYPHOR AG

(POLN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

EQS-Adhoc : Polyphor to extend period for its strategic evaluation by up to four weeks

07/30/2021 | 01:31am EDT
EQS Group-Ad-hoc: Polyphor AG / Key word(s): Statement 
Polyphor to extend period for its strategic evaluation by up to four weeks 
30-Jul-2021 / 07:30 CET/CEST 
Release of an ad hoc announcement pursuant to Art. 53 LR 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Allschwil, Switzerland, July 30, 2021 
Polyphor to extend period for its strategic evaluation by up to four weeks 
Polyphor AG (SIX: POLN) today provided an update regarding the recently announced evaluation of strategic options. This 
review has become necessary following the negative results of the FORTRESS study for balixafortide. The board of 
directors has resolved to extend the period for strategic evaluation of all options for the future of the Company by up 
to four weeks. 
The planned restructuring to reduce costs and create operational efficiencies is being completed with the reduction of 
around 20 employees following the finalization of the consultation process. 
For further information please contact: 
 
For Investors:          For Media: 
Hernan Levett           Dr. Stephan Feldhaus 
Chief Financial Officer Feldhaus & Partner 
Polyphor Ltd.           +41 79 865 92 56 
+41 61 567 16 00        feldhaus@feldhaus-partner.ch 
IR@polyphor.com 

About Polyphor Polyphor is a research driven clinical-stage, Swiss biopharmaceutical company committed to discovering and developing best-in-class molecules in oncology and antimicrobial resistance leveraging the company's leading macrocyclic peptide technology platform. Polyphor has finished patient enrollment of a Phase III trial of balixafortide (POL6326) in combination with eribulin in patients with advanced breast cancer. In addition, it has discovered and is developing the Outer Membrane Protein Targeting Antibiotics (OMPTA). OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria. The company's lead OMPTA program is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Polyphor is based in Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN). For more information, please visit www.polyphor.com.

Disclaimer This press release contains forward-looking statements which are based on current assumptions and forecasts of the Polyphor management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Polyphor's results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Polyphor disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise. ----------------------------------------------------------------------------------------------------------------------- End of ad hoc announcement -----------------------------------------------------------------------------------------------------------------------

Language:     English 
Company:      Polyphor AG 
              Hegenheimermattweg 125 
              4123 Allschwil 
              Switzerland 
Phone:        +41 61 567 1600 
Fax:          +41 61 567 1601 
E-mail:       info@polyphor.com 
Internet:     www.polyphor.com 
ISIN:         CH0106213793 
Valor:        POLN 
Listed:       SIX Swiss Exchange 
EQS News ID:  1222853 
 
End of Announcement EQS Group News Service 
=------------ 

1222853 30-Jul-2021 CET/CEST

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1222853&application_name=news 
 

(END) Dow Jones Newswires

July 30, 2021 01:30 ET (05:30 GMT)

All news about POLYPHOR AG
09/27Polyphor publishes invitation to Extraordinary General Meeting and announces financial ..
DJ
09/10POLYPHOR : Wraps Up Sale Of Inhaled Murepavadin To EnBiotix
MT
09/10Polyphor and EnBiotix announce closing of purchase agreement of Inhaled Murepavadin by ..
DJ
09/02GLOBAL MARKETS LIVE : Ford, Walmart, Apple, Volkswagen, Tesla...
09/01POLYPHOR : Signs All-Stock Merger Deal With Rare Disease Company EnBiotix
MT
09/01Polyphor and EnBiotix announce signing of merger agreement and sale of Inhaled Murepava..
DJ
09/01Polyphor AG signed a merger agreement to acquire EnBiotix, Inc.
CI
08/04POLYPHOR : Fails In Late-Stage Trial For Breast Cancer Combo Treatment
MT
08/03EQS-ADHOC : Polyphor provides final update on the Phase III FORTRESS study of balixafortid..
DJ
08/03Polyphor Provides Final Update on the Phase III FORTRESS Study of Balixafortide in Pati..
CI
More news
Financials
Sales 2021 1,00 M 1,08 M 1,08 M
Net income 2021 -41,4 M -44,7 M -44,7 M
Net Debt 2021 76,8 M 82,9 M 82,9 M
P/E ratio 2021 -0,53x
Yield 2021 -
Capitalization 23,6 M 25,5 M 25,4 M
EV / Sales 2021 100x
EV / Sales 2022 5,72x
Nbr of Employees 52
Free-Float 81,5%
Chart POLYPHOR AG
Duration : Period :
Polyphor AG Technical Analysis Chart | POLN | CH0106213793 | MarketScreener
Technical analysis trends POLYPHOR AG
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 1
Last Close Price 2,00 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
G÷khan Batur Chief Executive Officer
Hernan Levett Chief Financial Officer
Kuno Sommer Chairman
Daniel Obrecht Chief Scientific Officer
Frank T. Weber Chief Medical & Development Officer
Sector and Competitors
1st jan.Capi. (M$)
POLYPHOR AG-75.46%25
CSL LIMITED8.15%103 032
WUXI BIOLOGICS (CAYMAN) INC.18.58%64 160
SAMSUNG BIOLOGICS CO.,LTD.11.38%51 643
BIOGEN INC.19.13%43 475
ALEXION PHARMACEUTICALS, INC.0.00%40 336